Stocks of CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded higher last session on Wall Street, up 8.19% to $16.24.
According to the data, CymaBay Therapeutics Inc. (NASDAQ:CBAY) has 13 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $33.00 and a low of $15.00, we find $21.00. Given the previous closing price of $15.01, this indicates a potential upside of 39.91 percent. CBAY stock price is now 32.93% away from the 50-day moving average and 82.36% away from the 200-day moving average. The market capitalization of the company currently stands at $1.47B.
A total of 0 analysts have issued a hold rating and 13 have given it a buy rating. Brokers who have rated the stock have averaged $21.67 as their price target over the next twelve months.
With the price target of $18, UBS recently initiated with Buy rating for CymaBay Therapeutics Inc. (NASDAQ: CBAY).
In other news, McWherter Charles, President of R&D sold 21,746 shares of the company’s stock on Aug 18. The stock was sold for $249,359 at an average price of $11.47. Upon completion of the transaction, the President of R&D now directly owns 15,000 shares in the company, valued at $0.24 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 15, General Counsel Quinlan Paul T sold 5,000 shares of the business’s stock. A total of $59,550 was realized by selling the stock at an average price of $11.91. Insiders disposed of 222,093 shares of company stock worth roughly $3.61 million over the past 1 year. A total of 0.31% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CBAY stock. A new stake in CymaBay Therapeutics Inc. shares was purchased by NOVO HOLDINGS A/S during the first quarter worth $32,480,000. NICHOLAS INVESTMENT PARTNERS, LP invested $11,318,000 in shares of CBAY during the first quarter. In the first quarter, OPALEYE MANAGEMENT INC. acquired a new stake in CymaBay Therapeutics Inc. valued at approximately $9,203,000. UNISUPER MANAGEMENT PTY LTD acquired a new stake in CBAY for approximately $6,510,000. SOLEUS CAPITAL MANAGEMENT, L.P. purchased a new stake in CBAY valued at around $6,058,000 in the second quarter. In total, there are 189 active investors with 76.30% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $15.42 for CymaBay Therapeutics Inc. (NASDAQ: CBAY). During the past 12 months, CymaBay Therapeutics Inc. has had a low of $3.15 and a high of $15.90. As of last week, the company has a debt-to-equity ratio of 0.92, a current ratio of 12.50, and a quick ratio of 12.50. The fifty day moving average price for CBAY is $12.38 and a two-hundred day moving average price translates $8.97 for the stock.
The latest earnings results from CymaBay Therapeutics Inc. (NASDAQ: CBAY) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.01, beating analysts’ expectations of -$0.2 by 0.19. This compares to -$0.31 EPS in the same period last year. For the current quarter, analysts expect CBAY to generate $430k in revenue.
CymaBay Therapeutics Inc.(CBAY) Company Profile
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
